CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Does CJC-1295 Really Work? CJC 1295 Research Overview

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

50 WORDS

Short answer

A single subcutaneous dose of CJC-1295 with DAC raised mean plasma growth hormone two- to ten-fold for six days or more, and IGF-1 by 1.5- to three-fold for nine to eleven days. That comes from Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism in 2006 .

Key takeaways

CJC-1295 is a tetrasubstituted GHRH (1-29) analog that binds the pituitary GHRH receptor and amplifies the body's own growth hormone signal rather than replacing it.
The Teichman 2006 trial reported a terminal half-life of 5.8 to 8.1 days for the DAC form, with IGF-1 remaining elevated for nine to eleven days after a single dose.
Pulsatile GH secretion persisted under continuous GHRH-receptor stimulation, which contradicts the assumption that long-acting analogs flatten the natural rhythm.
No phase 3 efficacy data exists on body composition or clinical outcomes, so the honest answer in CJC 1295 research is that biomarkers moved and endpoints were never tested.
The D-Ala2, Gln8, Ala15 and Leu27 substitutions each block a specific degradation route: DPP-4 cleavage, deamidation and methionine oxidation respectively.
HPLC purity and peptide content are different measurements, and confusing them is the most common reason two laboratories report different results from the same nominal quantity.

We supply research-grade peptides to laboratories that read primary literature before they place an order. The question we field most often isn't about mechanism. It's whether the published data says what the internet claims it says.

Does CJC-1295 really work?

In controlled human trials, yes: the peptide reliably elevates growth hormone and IGF-1 in a dose-dependent way, with the DAC form showing a reported terminal half-life of 5.8 to 8.1 days. What CJC 1295 research has never demonstrated is an approved clinical outcome. It moves biomarkers, not endpoints.

The misconception worth clearing first is that the word 'works' gets used for two different things. Raising serum IGF-1 is a pharmacodynamic response, and it's well documented. Producing a measured change in body composition, recovery, or sleep architecture is a clinical endpoint, and no CJC-1295 trial was ever powered to show one. This piece covers the receptor mechanism, what each published study measured, how the DAC and no-DAC forms differ in kinetics, and which handling failures quietly wreck CJC 1295 research results before an assay ever runs.

How a GHRH analog talks to the pituitary

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), built on the first 29 amino acids of the native hormone, the shortest fragment that retains full biological activity. It binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on pituitary somatotroph cells, and switches on the Gs protein, adenylyl cyclase, cAMP, protein kinase A cascade that transcribes new growth hormone and releases stored GH granules.

So what does CJC 1295 do, in one sentence? It amplifies the pituitary's own GH signal rather than supplying growth hormone from outside.

Four amino acid substitutions define the molecule, and each one exists for a reason. D-Ala at position 2 blocks dipeptidyl peptidase-4 (DPP-4), the enzyme that cleaves native GHRH within minutes of release. Gln at position 8 removes an asparagine prone to deamidation. Ala at 15 improves bioactivity. Leu at 27 replaces a methionine that would otherwise oxidise. That tetrasubstituted backbone is what's sold as CJC-1295 no DAC, also called modified GRF (1-29).

The DAC version adds one more thing: a maleimidopropionyl linker that forms a covalent bond with cysteine-34 on circulating serum albumin. Once bound, the peptide travels as an albumin conjugate and largely escapes renal clearance. That's the entire reason its duration is measured in days instead of minutes.

One point the literature is unambiguous about: the peptide does not override somatostatin, the hypothalamic brake on GH release. In our experience, that's the mechanism detail buyers miss most often, and it explains why secretion stays rhythmic.

What the published trials actually measured

The core CJC 1295 research base is small, human, and concentrated in 2005 and 2006. The anchor paper is the Teichman study: randomised, double-blind and placebo-controlled, in healthy adults receiving single and multiple subcutaneous doses of CJC-1295 with DAC. Reported terminal half-life was 5.8 to 8.1 days. Mean GH rose two- to ten-fold for six days or more after a single administration, and IGF-1 rose 1.5- to three-fold for nine to eleven days. Trial arms ran from roughly 30 to 60 micrograms per kilogram. Those are reference figures from a clinical protocol, not instructions for anybody.

A companion paper by Ionescu and Frohman in the same journal that year asked a sharper question: does continuous GHRH-receptor stimulation flatten the natural GH rhythm? It didn't. Pulsatile secretion persisted, with trough concentrations elevated and pulse structure preserved. In GHRH-deficient knockout mice, once-daily CJC-1295 normalised growth, which is about as clean a mechanistic confirmation as preclinical work offers.

Here's where most summaries of cjc-1295 research studies go wrong, and it has nothing to do with efficacy. GH is pulsatile and captured only by frequent venous sampling. IGF-1 is stable and integrates GH exposure across days. When an article quotes a ten-fold GH increase, that's a peak ratio in one dose arm at one timepoint, not a steady state. IGF-1 is the honest integrator. Quote that instead.

What's absent matters just as much. Development never advanced through late-stage efficacy trials, so the CJC 1295 research literature contains no phase 3 body composition endpoints at all.

Purity, storage, and why two labs get different results

Two vials carrying the same label can behave differently, and the cause is almost always analytical rather than biological. HPLC purity tells you what fraction of the peptide present is the target sequence. Peptide content tells you how much of the vial's mass is peptide at all, rather than counterion salt and bound water. A lyophilised vial can read 98% pure by HPLC and still deliver less net peptide than assumed, because trifluoroacetic acid counterion and residual moisture aren't peptide. Mass spectrometry confirmation of molecular weight is the check that catches a truncated or misassembled sequence HPLC alone can miss.

Storage is the other silent variable. Lyophilised GHRH analogs hold best at -20°C, protected from light. Once reconstituted, refrigeration at 2-8°C with minimal freeze-thaw cycling is standard laboratory practice. Those Gln8 and Leu27 substitutions exist precisely because deamidation and oxidation degrade this scaffold, and degradation doesn't change how a clear solution looks.

Reading a certificate of analysis is a skill. Batch number, sequence, molecular weight, chromatogram and synthesis date have to be read together, not in isolation. Every batch we ship is documented in our published COA library, and our CJC-1295 No DAC 10mg listing carries its own batch paperwork.

A compliance note, stated plainly: CJC-1295 is not an FDA-approved drug, it's supplied strictly for cjc-1295 laboratory research, and nothing here is guidance for use in people or animals. Anyone with a personal health question should speak with a licensed physician, and for an animal, talk to their veterinarian. Serious CJC 1295 research starts with that boundary.

CJC 1295 research at a glance: two forms and two neighbours

The most common source of confusion in this space is treating CJC-1295 as one compound when it's really two, with very different kinetics. This table sets both forms alongside the two peptides they're most often compared with.

Compound	Receptor and mechanism	Reported duration	What the literature reports	Bottom line for lab work
CJC-1295 with DAC	GHRH receptor agonist, albumin-bound via Cys-34	Terminal half-life reported at 5.8 to 8.1 days	Sustained 2-10x GH elevation and 1.5-3x IGF-1 elevation after single dosing in healthy adults	The only form with published human pharmacokinetic data of this depth; long exposure window suits multi-day sampling designs
CJC-1295 no DAC (modified GRF 1-29)	Same GHRH receptor, no albumin linker	Short, measured in minutes rather than days	Far less standalone human trial data; used widely as a short-pulse GHRH input in models	Better suited to studies isolating a single secretory pulse rather than chronic receptor tone
Ipamorelin	GHS-R1a (ghrelin receptor) agonist, a separate pathway	Short-acting	Selective GH release with limited effect on cortisol and prolactin in published work	Different receptor entirely; frequently paired in research designs testing pathway synergy
Tesamorelin	GHRH analog, stabilised trans-3-hexenoic acid modification	Intermediate	The GHRH analog that did progress through late-stage clinical development	Useful literature comparator; research-grade material is not the same thing as an approved prescription product

What If: common laboratory scenarios

These are the three questions that reach our inbox most often from buyers running CJC 1295 research protocols.

What if the vial arrived warm after shipping?

Check whether the material is still lyophilised before assuming it's compromised. Lyophilised peptides are considerably more thermally forgiving than reconstituted solution, and short ambient excursions during transit are routine in peptide logistics. Reconstituted material is the fragile state, since hydrolysis and deamidation accelerate in aqueous solution. If the powder is intact, dry and uniform rather than clumped or discoloured, transfer it to -20°C storage and record the excursion in your batch log. If you received it as solution and it sat above 8°C for an extended period, treat potency as unverified.

What if there's no measurable GH response in the assay?

Confirm your sampling timing before you question the compound. GH is secreted in pulses, so a single draw at the wrong interval can miss a substantial response entirely, which is exactly why the published work used frequent serial sampling. IGF-1 is the steadier readout because it integrates GH exposure across days. Beyond timing, the usual culprits are somatostatin tone in the model, receptor desensitisation under continuous stimulation, and peptide that degraded in storage. Re-run the certificate of analysis against your batch before rewriting the protocol.

What if the certificate lists a molecular weight that doesn't match?

Stop and compare the stated sequence against the mass spectrometry result on the same document. A mismatch of a few daltons usually points to a salt form or a deamidated variant; a larger gap suggests a truncated sequence or the wrong peptide entirely. Molecular weight for modified GRF (1-29) differs from the DAC-conjugated version, and mixing up the two specifications accounts for a surprising share of these queries. Any unresolved discrepancy is a reason to quarantine the batch, not to proceed carefully.

The honest limits of the evidence base

Here's the honest answer: CJC 1295 research proves the pharmacology and proves almost nothing about outcomes. Two small human trials from 2006 plus rodent work is not a mature evidence base, and everything written since largely re-quotes those same numbers. The peptide unquestionably raises GH and IGF-1. Whether that produces anything a person would notice was never tested in a controlled trial, because development stopped before those trials were run. Anyone claiming otherwise is extrapolating from a half-life curve, not citing data.

Researchers comparing GHRH-pathway compounds can read our deeper breakdown at the CJC-1295 resource page, review batch documentation in the COA library, and see the full catalogue of research compounds, including Ipamorelin 10mg and Tesamorelin 10mg, across our research peptide range.

CJC 1295 research answers a narrower question than the internet asks of it. The peptide does what a GHRH analog is supposed to do: it raises growth hormone, it raises IGF-1, and the albumin-bound form sustains both for days. Whether any of that translates into something measurable at the level of a whole organism was never established, because the studies that would have settled it were never funded. That gap isn't a flaw in the molecule. It's a hole in the literature, and no amount of forum consensus fills it in.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

In published human trials it does exactly what a GHRH analog should: Teichman et al. (2006) reported growth hormone elevated two- to ten-fold for six days or more and IGF-1 raised 1.5- to three-fold for nine to eleven days after a single dose. Those are biomarker results, not clinical outcomes.

CJC-1295 binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells and activates the cAMP and protein kinase A cascade, which drives transcription and release of the body's own growth hormone. Elevated GH then stimulates hepatic IGF-1 production. It amplifies an existing signal rather than supplying hormone directly.

Yes at the pharmacological level, with an important limit. The evidence consistently shows dose-dependent GH and IGF-1 elevation in healthy adults, and preserved pulsatile secretion under sustained receptor stimulation. No phase 3 trial measured body composition or any other clinical endpoint, so efficacy beyond biomarkers remains untested.

It's a 29-amino-acid GHRH analog with four substitutions: D-Ala2 blocks DPP-4 enzymatic cleavage, Gln8 prevents deamidation, Ala15 raises bioactivity and Leu27 stops methionine oxidation. The DAC version adds a linker that binds covalently to albumin cysteine-34, extending circulation from minutes to a reported 5.8 to 8.1 days.

We don't provide dosing figures, because CJC-1295 is supplied strictly as a research compound and is not approved for human or veterinary use. The published trial administered single subcutaneous doses in the range of roughly 30 to 60 micrograms per kilogram to study participants under clinical supervision. That's a literature reference only.

PubMed is the primary index. The foundational entries are Teichman et al. in the Journal of Clinical Endocrinology & Metabolism (2006) on pharmacokinetics and GH response, and the Ionescu and Frohman paper in the same journal that year on preserved pulsatility. Most other CJC 1295 research papers cite these two.

The published human pharmacokinetic data covers the DAC form, which binds serum albumin and shows a half-life measured in days. Modified GRF (1-29), the no-DAC version, shares the same receptor mechanism but clears in minutes and has far less standalone human trial data behind it.

CJC-1295 can be purchased in most jurisdictions as a research chemical for laboratory use. It is not an FDA-approved drug and is not sold or labelled for human or veterinary consumption. Buyers are responsible for confirming their own institutional, local and import requirements before ordering.

Pricing varies widely by vial size, verified purity, batch documentation and supplier. Cost differences usually track analytical rigour rather than the peptide itself, since third-party HPLC and mass spectrometry testing per batch adds real expense. Material priced well below market typically lacks batch-level certificates of analysis.

The published human work reported injection-site reactions and transient flushing as the most common tolerability findings, without serious adverse events in those small cohorts. The sample sizes were limited and follow-up was short, so the safety picture is best described as incomplete rather than reassuring.

Lyophilised peptide holds best at -20°C, protected from light and moisture. After reconstitution, standard practice is refrigeration at 2-8°C with freeze-thaw cycling minimised, since hydrolysis, deamidation and aggregation accelerate in aqueous solution. Degradation is not visible in a clear solution, so batch logs matter more than appearance.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA